Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Blood (2012) 120 (21): 800.

https://doi.org/10.1182/blood.V120.21.800.800

Published: 2012

Journal Articles

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis

Jeffrey W Tyner, PhD, Heidi Erickson, Stephen Oh, MD, PhD, Jason R. Gotlib, Michael W.N. Deininger, MD, Brian J. Druker, Marc Loriaux, MD, PhD

Blood (2008) 112 (11): 2519.

https://doi.org/10.1182/blood.V112.11.2519.2519

Published: 2008

Journal Articles

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Michael W.N. Deininger, MD, Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, Jerald Radich

Blood (2008) 112 (11): 3236.

https://doi.org/10.1182/blood.V112.11.3236.3236

Published: 2008

Journal Articles

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Richard D. Press, MD, PhD, Stephanie G Willis, Jennifer Laudadio, Michael J. Mauro, MD, Michael W.N. Deininger, MD

Blood (2008) 112 (11): 1108.

https://doi.org/10.1182/blood.V112.11.1108.1108

Published: 2008

Journal Articles

Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

Thomas G.P. Bumm, Jeffrey W Tyner, PhD, Jutta Deininger, Marc Loriaux, Jonathan VanDyke, Brian J. Druker, Christopher J Burns, Emmanuelle Fantino3, Michael W.N. Deininger, MD

Blood (2008) 112 (11): 856.

https://doi.org/10.1182/blood.V112.11.856.856

Published: 2008

Journal Articles

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill Chang, MD, PhD, Vincent T Bicocca, Stephen Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. den Boer, C. M Zwaan, MD, PhD, Jason R. Gotlib, Michael W.N. Deininger, MD, Brian J. Druker

Blood (2008) 112 (11): 758.

https://doi.org/10.1182/blood.V112.11.758.758

Published: 2008

Journal Articles

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy.

Jennifer Laudadio, MD, Michael W.N. Deininger, MD, Michael J. Mauro, MD, Brian J. Druker, MD, Richard D. Press, MD, PhD

Blood (2007) 110 (11): 1953.

https://doi.org/10.1182/blood.V110.11.1953.1953

Published: 2007

Journal Articles

RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients.

Jeffrey W. Tyner, PhD, Stephanie Willis, BS, Michael W.N. Deininger, MD, PhD, Brian J. Druker, MD

Blood (2007) 110 (11): 208.

https://doi.org/10.1182/blood.V110.11.208.208

Published: 2007

Journal Articles

Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission.

Thomas G.P. Bumm, MD, Amy Hanlon Newell, PhD, Jay Oost, Jonathan VanDyke, Susan B. Olson, PhD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2007) 110 (11): 36.

https://doi.org/10.1182/blood.V110.11.36.36

Published: 2007

Journal Articles

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

Thomas G.P. Bumm, MD, Jonathan VanDyke, Marc Loriaux, MD, PhD, Carolyn Gendron, Lisa G. Wood, PhD, RN, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2007) 110 (11): 675.

https://doi.org/10.1182/blood.V110.11.675.675

Published: 2007

Journal Articles

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

Thomas O’Hare, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Matthew J. Wong, Caitlyn A. Smith, Amie S. Corbin, Sean Buchanan, PhD, Katayoun A. Jessen, PhD, Crystal Tang, Kevin Holme, PhD, Stephen K. Burley, MD, PhD, Michael W.N. Deininger, MD, PhD

Blood (2006) 108 (11): 1373.

https://doi.org/10.1182/blood.V108.11.1373.1373

Published: 2006

Journal Articles

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Anupriya Agarwal, PhD, Thomas G.P. Bumm, MD, Amie Corbin, Thomas O’Hare, PhD, Marc Loriaux, MD, PhD, Stephanie G. Willis, Jutta Deininger, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2006) 108 (11): 742.

https://doi.org/10.1182/blood.V108.11.742.742

Published: 2006

Journal Articles

Monitoring Imatinib Resistance with a “Polony” Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).

Valentina Nardi, MD, Tal Raz, PhD, Xinyu Chao, Catherine J. Wu, MD, Richard Stone, MD, Ilene Galinsky, RN, NP, Martha Wadleigh, MD, Michael W.N. Deininger, MD, PhD, George Church, PhD, Jun Zhu, PhD, George Q. Daley, MD, PhD

Blood (2006) 108 (11): 837.

https://doi.org/10.1182/blood.V108.11.837.837

Published: 2006

Journal Articles

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

Richard D. Press, MD, PhD, Stephanie Willis, Carole Rempfer, Michael J. Mauro, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD

Blood (2006) 108 (11): 2152.

https://doi.org/10.1182/blood.V108.11.2152.2152

Published: 2006

Journal Articles

Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen.

Michael W.N. Deininger, MD, PhD, Heather Bradeen, MD, Taiping Jia, Thomas O’Hare, PhD, Stephanie G. Willis, Frank Lee, PhD, Brian J. Druker, MD

Blood (2005) 106 (11): 691.

https://doi.org/10.1182/blood.V106.11.691.691

Published: 2005

Journal Articles

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Lucy C. Crossman, MD, Thomas O’Hare, PhD, Thoralf Lange, MD, Stephanie G. Willis, Eric P. Stoffregen, Amie S. Corbin, Stephen G. O’Brien, MD, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD, Peter G. Middleton, PhD, Michael W.N. Deininger, MD, PhD

Blood (2005) 106 (11): 1530.

https://doi.org/10.1182/blood.V106.11.1530.1530

Published: 2005

Journal Articles

A Bcr-Abl Mutant Lacking Direct Binding Sites for the Grb2, Cbl and CrkL Adapter Proteins Fails to Induce Leukemia in Mice.

Kara J. Johnson, Ian J. Griswold, PhD, Amie Corbin, Michael W.N. Deininger, MD, PhD, Brian J. Druker, MD

Blood (2004) 104 (11): 718.

https://doi.org/10.1182/blood.V104.11.718.718

Published: 2004

NARROW

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy.

RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients.

Chromosomal Abnormalities in the Early Stem Cell Population of CML Patients in Complete Cytogenetic Remission.

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Monitoring Imatinib Resistance with a “Polony” Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen.

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

A Bcr-Abl Mutant Lacking Direct Binding Sites for the Grb2, Cbl and CrkL Adapter Proteins Fails to Induce Leukemia in Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only